Phaseline

Companies › Adneuris Therapeutics

Adneuris Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other, Psychiatry; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cebranopadol
Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist
OPRL1, OPRK1, OPRD1, OPRM1Phase 3Pain; Chronic PainJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07845071CebranopadolPhase 3PainOtherJan 2027
NCT07874620CebranopadolPhase 2Chronic PainPsychiatryMar 2027

Targets

OPRL1 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Alkermes Boulder Care Inventage Lab. Johnson & Johnson (Janssen) Tioga Pharmaceuticals

Companies built like this

AgelessRx Alkermes Syndeio Biosciences Axsome Therapeutics Trevi Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.